Nutritional and Metabolic Diseases

Symptoms and General Pathology

All Conditions

Obesity

The IER+MED group intervention will be to restrict 70% energy (34%, 33% and 33% distribution of protein, carbohydrate, and fat, respectively) on 2 days and follow the MED diet (25%, 45%, 30%) and meet their estimated energy requirement (EER) for the other 5 days each week. Participants will also be asked to follow a moderate exercise program (1 hour of walking five days a week).

The DASH group intervention will be to follow the DASH diet and meeting a distribution of macronutrients of 20% protein, 53% carbohydrate, and 30% fat and meet their EER. Participants will also be asked to follow a moderate exercise program (1 hour of walking five days a week).

Follow a Mediterranean diet 5 days per week and follow intermittent energy restriction 2 days per week.

IER+MED group

Follow the distribution of macronutrients and food groups prescribed by the DASH diet 7 days per week.

DASH group

Loic Le Marchand, MD, PhD

Carol J Boushey, PhD, RDN

Unhee Lim, PhD

This pilot study aims to develop a study design to test the difference between a fasting diet and a heart healthy diet, assess participants' adherence to the study design, and to test whether either diet helps to reduce fat wrapped around the organs in the stomach area and total body fat in East Asian American adults. 70 men and women residents of Oahu Hawai'i, aged 35-55, who are overweight or obese and have moderate to high amounts of fat around organs in the stomach area, of Japanese, Chinese, or Korean ancestry, will be equally distributed to either the fasting diet or the heart healthy diet and asked to follow this diet for the 12-week study. Each diet has set requirements for energy, protein, carbohydrates, and fat. The fasting diet has two days of fasting, where participants will be asked to follow a low carbohydrate- low energy diet, and five days of a balanced diet without any energy restriction (the Mediterranean diet). The other group will follow a heart healthy diet (Dietary Approaches to Stop Hypertension diet) for all seven days without any energy restriction. Both groups will be asked to follow a moderate exercise program (one hour of walking five days a week). Dietitians will provide information on diet and exercise requirements to the participants at the start of the study. Dietitians will contact the participants seven times, primarily by phone, to offer support and to check if the participants are following prescribed diet and exercise plans. Participants will use a mobile phone app to take images of all foods and drinks for four days at the beginning, middle and end of the 12-week study. Body measurements, including measurements of body fat, will be taken at the beginning and end of the study by trained clinic staff. The analysis of the food images, participants' self-reported compliance to diet and exercise plans, and body measurements will be used to determine if the study design and participant compliance to the study are successful, and to assess which diet is better at reducing total body fat and fat around the organs in the stomach region.

Background and rationale: East Asian adults are known to have higher levels of visceral adiposity than whites, African Americans, and Hispanic adults in the US. This visceral fat deposition, because of its close proximity to the portal vein, has greater metabolic activity and is associated with a greater risk of cardiometabolic diseases and possibly certain cancers (e.g., breast and colorectal cancers). Newly introduced weight loss interventions, specifically, intermittent energy restriction (IER), have been proposed to be as effective as continuous energy restriction, achieve higher and long-term compliance, and may predominantly result in a decrease in visceral fat. Thus, implementing this novel weight loss intervention among East Asian Americans with high visceral fat deposition would be particularly beneficial .

Goal: This study aims to demonstrate the feasibility to conduct an intermittent energy restriction (IER) nutritional intervention aimed at reducing visceral adiposity in overweight Asian Americans middle-aged adults.

1. To finalize and implement a protocol for an IER intervention plus exercise with the goal of reducing visceral fat in overweight adult East Asian Americans (EAA). The protocol will include an intensive dietary intervention and an exercise program administered by a dietitian through individual meetings and the use of new technologies to monitor dietary compliance.
2. After eligibility screening, 70 individuals will be randomized to either the intensive intervention diet group or to a non-intensive intervention (active comparator) diet group for 12 weeks. The intensive intervention group will follow a low carbohydrate- low energy IER diet for two consecutive days, and the Mediterranean (MED) diet for the other five days and meet estimated energy requirements (IER + MED group). The active comparator group will follow the Dietary Approaches to Stop Hypertension (DASH) diet for all seven days and meet estimated energy requirements (DASH group). With an expected attrition rate of \~25%, the investigators expect \~50 participants to complete the study.
3. To evaluate study retention, protocol adherence, effect size of the intervention on body weight, total adiposity, DXA measured visceral fat (main outcome), estimated visceral adipose tissue area, and selected clinical measures (e.g., waist circumference, hip circumference).

Design: Randomized lifestyle intervention trial to compare the effects of two twelve-week diets - (i) an IER + MED diet versus (ii) DASH diet- on DXA quantified visceral fat deposition distribution in overweight/obese men and women. Both intervention groups will be asked to follow a moderate exercise program (1 hour of walking five days a week). The research will be carried out in the University of Hawaii Cancer Center (UHCC). The investigators will determine and compare the primary and secondary endpoints at least five days after the last 2 energy-restricted days to a corresponding day of the week in the DASH group at the completion of the 12th week of IER+MED or DASH diets.

Assessing dietary intervention adherence: Dietary intake of energy, fat (monounsaturated fatty acids (MUFA), Polyunsaturated fatty acids (PUFA) and saturated fat), carbohydrate, protein, dietary fiber and alcohol will be assessed prior to the first week of intervention, the 5-6th week, and the 12th week. Participants will capture images of foods eaten and consumed over four days (i.e., before and after images of each eating occasion). A mobile app designed to seamlessly take images of foods/beverages will be loaded to onto each participant's mobile telephones for free and removed at the end of the study. Physical activity level will be assessed at baseline using a physical activity questionnaire.

Advice, support and monitoring in both diet groups Foods eaten for the IER+MED and DASH diets will be self-selected by the participants and not provided by the study team. The IER+MED and DASH groups will receive clear instructions on how to follow the allocated diet in a face-to-face dietary consultation with one of the trial dietitians (45- 60 minute appointment) at the UHCC. Both groups will receive comprehensive written instructions of how to follow the diets at home, including recommended portion sizes and recipes and suggested meal plans. Both groups will receive appropriate behavioral techniques to promote adherence to diets (i.e., self-monitoring of diet and goal setting).

Participants will be contacted by telephone by an allocated dietitian one week after randomization to check that they have started the diet, to assess understanding of the diet and to provide any trouble shooting advice. Participants will be contacted by an allocated dietitian with weekly phone calls in weeks 1 to 4 to discuss adherence and any problems with the diet; and with every other week phone calls in weeks 5 to 12. Both groups will be asked to record 4-day dietary records with the mobile food record at Week 6 and Week 11. This will allow assessment to adherence of the allocated diets and better tailor dietary advice. Participants will be asked to report overall compliance to the diet and physical activity plans using a scale of 0-10 for each, on the weekly and fortnightly phone calls with the dietitian. The IER+MED group will also be asked to record adherence to the 2-day IER using a scale of 0-2. All participants will also be advised to become more active, walking at least one hour per day five days per week. The intermittent energy restriction (IER) group will be encouraged to walk on the non-IER days.

Post-Study At the end of the study all participants will be offered advice on continued weight loss and/or weight loss maintenance if they have reached a target weight and this is appropriate. This will include advice regarding preferred diet, i.e., IER+MED or DASH. If resources permit, the investigators will recontact participants six and twelve months after the end of the intervention to assess dietary intake, physical activity and body weight.

Statistical Considerations Statistical analysis will be conducted within Epidemiology Program, UHCC. The primary aim is to determine changes in percentage visceral fat between the IER+MED diet and the DASH diet over a 3 months period. The sample size of 25 participants per group has been chosen to detect a difference of 15 percentage points in the reduction in visceral fat between the two different diets, assuming an estimated 25% drop-out rate. Calculations assume a two-sided t-test with estimated standard deviation of 10% and the conventional 5% significance level. The primary analysis will be performed on an intent-to-treat principle, where all participants will be analyzed by randomization group, regardless of compliance.

The primary endpoints of visceral fat measurements will be regressed on randomization group and time point, as well as potential confounders, using a mixed model approach accounting for the repeated measures at baseline, and 6 and 12 weeks. The primary hypothesis will be tested by a contrast F test comparing the difference between groups in the change from baseline to 12 weeks. The 6 month assessment will be similarly tested to understand the trend over time. If there is evidence of a linear change in fat over time, time will be entered as a continuous variable and the slope will be compared between groups. Visceral fat will be modelled as an absolute area and as percentage of total area. The secondary analysis will analyze relationship between the IER+MED intervention and total adiposity.

Ethical Considerations The study will be performed in accordance with the ethical principles in the Declaration of Helsinki and the University of Hawaii operational and ethical guidelines for research and other applicable regulatory requirements.

Participant information and consent Consent to enter the study will be sought from each participant only after a full explanation has been given, information has been provided and time allowed for consideration. The right of the participant to refuse to participate without giving reasons will be respected.

Discontinuation and withdrawal Participants are free to withdraw from the study at any time, without prejudice to further treatment. Participants may also be discontinued from the study at any time, at the discretion of the investigator. Requests by the participant to be withdrawn from the study should be made through the principal investigator.

Confidentiality After the participant has consented, any information from the study will be stored on a secure password-protected computer that will be accessible only to the research team. Trial data on anthropometry and activity meter data will be kept in a secure computer at the UHCC. The food \& beverage images from the 4-day mobile food records will be kept on a secure server.

Data Handling and Record Keeping All data will be kept strictly confidential. Any individual volunteering to participate will be assigned a code number, with the link to identifying information only available to the few study staff that require this information. Identifying information will be maintained in separate secure computer files from the remainder of the data. All forms will be stored in locked file cabinets, and those with identifying information will be stored separately from the other forms. No analysis will ever identify participants individually.

Randomized controlled trial. Participants will be randomized to either the IER+Med diet or the DASH diet for 12 weeks.

Participants will be provided with healthful dietary information but will not be told what diets their diet plans are based on. Participants in the IER+MED diet group will be told they are on diet plan 1 and participants in the DASH diet group will be told they are on diet plan A. The research dietitians will know which diet plan each participant is on, however; all other clinic staff who assess outcomes measures will be blinded to each participant's diet group.

The Healthy Diet and Lifestyle Study

Obesity, Body Fat Distribution, and Cancer Risk in the Multiethnic Cohort Study

VAT (cm2) measured at L4-L5 with Dual-energy X-ray absorptiometry (DXA)

Insulin, Glucose, C-reactive protein (CRP), Interleukin-6 (IL-6), Adipokines (leptin and adiponectin), Insulin-like growth factor-1 (IGF-1), and Serum Lipids

The William and Ellen Melohn Endowed Research Fund

University of Hawaii

Associate Research Professor

Nutrition Disorders

Nutritional intervention will be initiated in patients at risk of overweight and obesity. A targeted nutritional intervention will be carried out, which will include consultation on dietary habits and physical activity as determined by diet and physical activity records. Consultations will be aimed at improving lifestyle and maintaining an adequate body weight.

nutritional interventions

Tomáš Kepák, MUDr.

Lucie Štrublová, Mgr.

Julie Bienertová-Vašků, Prof.

Jan Kučera, Ph.D.

Viera Bajčiová, MUDr.

Hana Hrstková, Prof.

Jaroslav Štěrba, Prof.

NUTRITION CCS is a cross-sectional, descriptive study to assess the relationship between body composition and demographic, socioeconomic status, treatment modalities and blood samples of survivors who were in remission. The study was conducted in the Clinic for childhood cancer survivors. The clinic is attended by patients older than 18 years and was built in 2016 at the St. Anne's Hospital in Brno.

NUTRITION CCS is a cross-sectional, descriptive study to assess the relationship between body composition and demographic, socioeconomic status, treatment modalities and blood samples of survivors who were in remission.

Objectives of the study

1. to determine the prevalence (incidence) of nutritional disorders, especially obesity and metabolic syndrome, in cured paediatric cancer patients in adulthood;
2. to investigate the role of adipokines in the development of cardiometabolic complications in this group of patients; 3. to determine whether targeted dietary and lifestyle interventions can lead to improvements in nutritional status and subjectively perceived quality of life of treated paediatric cancer patients in adulthood and objectively assessed cardiometabolic risk

Patients will undergo analysis of peripheral blood (serum or plasma) or urine including characterization of adipokine profiles/metabolites by targeted or untargeted proteomic approach using mass spectrometry (NanoLC/ESI LTQ-Orbitrap MS/MS) or immunoassays (LUMINEX, ELISA) to identify approximately 15-20 molecules associated with cardiometabolic risk;

Nutrition Childhood Cancer Survivors

Nutritional Status of Cured Pediatric Cancer Patients in Adulthood, the Role of Adipokines in the Development of Cardiometabolic Complications and Desirable Nutritional Interventions

Define the relationship between the levels of selected adipokines and the risk of selected chronic diseases, specifically cardiometabolic diseases.

Determine the number of patients with a high body fat percentage. In these patients, monitor the responses of selected adipokine levels to targeted nutritional intervention leading to fat mass reduction.

St. Anne's University Hospital Brno, Czech Republic

Masaryk University

Neoplasms

Nervous System Diseases

Gland and Hormone Related Diseases

Musculoskeletal Diseases

Rare Diseases

Syndrome

Adenoma

Pituitary Diseases

Cushing Syndrome

Acromegaly

Hypopituitarism

Endocrine System Diseases

Pituitary Neoplasms

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Hypothalamic Diseases

Brain Diseases

Central Nervous System Diseases

Bone Diseases

Bone Diseases, Endocrine

Overweight

Overnutrition

Body Weight

Adrenocortical Hyperfunction

Adrenal Gland Diseases

Endocrine Gland Neoplasms

Hypothalamic Neoplasms

Supratentorial Neoplasms

Brain Neoplasms

Central Nervous System Neoplasms

Nervous System Neoplasms

Cushing's Syndrome

Hyperadrenalism

The goal of this observational study is to evaluate, retrospectively and prospectively, the effect of different hormonal and neuropeptide dysfunctions on the body composition of patients suffering from hypothalamic-pituitary pathologies, and to evaluate the potential beneficial effect of surgical and medical treatments with agonists and antagonists of hypothalamic neuropeptides, currently available, on the development and treatment of adiposity and negative cross-talk between adiposity and muscle/bone tissue

Neuroendocrine Mechanisms in Adiposity: An Integrated Approach to the Characterization of Potential Pharmacological Novel Targets Based on Experimental and Clinical Models

The study aims to evaluate, retrospectively and prospectively, the effect of different hormonal and neuropeptide dysfunctions on the body composition of patients suffering from hypothalamic-pituitary pathologies

IRCCS San Raffaele

Professor of Endocrinology and Metabolism

Skin and Connective Tissue Diseases

Breast Neoplasms

Insulin Resistance

Breast Diseases

Skin Diseases

Hypoglycemic Agents

All Drugs and Chemicals

Reproductive Control Agents

Central Nervous System Depressants

Other Dietary Supplements

Insulin

Insulin, Globin Zinc

Estradiol 17 beta-cypionate

Estradiol 3-benzoate

Estradiol

Polyestradiol phosphate

Mitogens

Benzocaine

Estropipate

Estrone

Tannic Acid

Women randomized to the exercise intervention arm completed a one year aerobic exercise intervention of 225 minutes/week.

Women randomized to the control arm were asked to maintain their regular lifestyle which meant no changes to their exercise or dietary intake. Women eligible for this trial were inactive and hence were expected not to increase their levels of physical activity in the control arm.

Women in the exercise arm underwent a year-long exercise intervention of five days per week of 45 minutes/session of moderate-vigorous intensity aerobic exercise.

Aerobic exercise intervention

Christine M Friedenreich, PhD

The purpose of the ALPHA Trial is to examine the physiologic changes that occur in a woman's body when she begins exercising that may be related to a change in her risk of getting breast cancer.

The goal of this study is to examine how a one-year exercise intervention, as compared to a usual sedentary lifestyle, influences specific biologic mechanisms that are hypothesized to be operative in the association between physical activity and breast cancer risk. These biologic mechanisms include sex hormone concentrations (estrone, estradiol and sex-hormone binding globulin); measures of adiposity and obesity; mammographic density; insulin-like growth factors; and insulin resistance.

A two-centered, two-armed randomized controlled trial (RCT) of exercise and risk factors for breast cancer will be conducted. Approximately 334 postmenopausal, sedentary women will be recruited to the study. Participants will be randomized to one of two groups: an exercise intervention, or a control group. The intervention group will undertake five weekly exercise sessions of 60 minutes each; three will be facility-based and two will be home-based each week. The Edmonton and Calgary exercise oncology facilities will be working in collaboration, and each will include both the controls and exercise intervention arms of the trial. The exercise intervention will last for 12 months. The control group will be asked not to change their usual level of activity during that time.

Baseline assessments will be obtained of serum sex hormones (estrone and estradiol), measures of obesity and adiposity, mammographic density, serum insulin growth factor (IGF)-1, insulin resistance, aerobic capacity, and psychosocial health measures. At the end of the study, all baseline assessments will be repeated and compared between the two groups.

This study will specifically address identified gaps in knowledge, in terms of examining the simultaneous effect of physical activity on several biologic mechanisms in a controlled trial setting, building on evidence from the only other randomized controlled trial on this topic. Strengths of the proposal include the multi-centered setting (utilizing facilities in both Calgary and Edmonton), and the collaboration of an experienced multi-disciplinary research team from across North America.

Alberta Physical Activity and Breast Cancer Prevention (ALPHA) Trial

The effect of the exercise intervention on sex steroid and adiposity levels after one year is examined.

The effect of the exercise intervention after one year is examined.

Canadian Breast Cancer Research Alliance

University of Alberta

University of Calgary

AHS Cancer Control Alberta

Scientific Leader and Principal Investigator

Inflammatory Breast Neoplasms

Inflammatory Breast Cancer

Performance of measurements of adiposity, extra collection of blood samples

Prospective data and sample collection

Marion Maetens, PhD

Tatjana Geukens, MD

Christine Desmedt, PhD

Giuseppe Floris, MD PhD

FATLAS is a prospective, interventional, non Investigational Medicinal Product (IMP) study aiming to characterize the micro- and macroenvironment of breast cancer according to patient adiposity in different histological and molecular subtypes.

The macroscopic profiling of the patient's adiposity will be based on Body Mass Index (BMI), bioimpedance analysis and waist-to-hip ratio. Blood samples will be taken for lipidomic analyses and for hormonal and immuno assays. Microscopic profiling of adiposity and inflammation will be done on fresh frozen (FF) and Formalin-Fixed Paraffin-Embedded (FFPE) samples from the tumour resection specimen and will consist of histological characterization, immuno assays, multiplex immunohistochemistry, DNA sequencing and single nuclei RNA sequencing both in the tumour and in adjacent normal mammary tissue.

FATLAS: Comprehensive Multi-level Characterization of Systemic and Mammary Adiposity in Breast Cancer Patients.

Calculated: body mass (kg) divided by height squared (m²)

Single nucleus RNA sequencing using 10X Genomics Platform after dissociation of tissue into single nuclei

Number of T-cells per population using immunohistochemical phenotypic markers of cell type and of exhaustion.

Time of activity of different intensities and time of sedentarity, evaluated using the Global Physical Activity Questionnaire (GPAQ) of the World Health Organisation (WHO) (scale: minutes per day, range \[0 - 1440\]). The higher the score for activity the better, the lower the score for sedentarity the better.

Pittsburgh Sleep Quality Index (PSQI) score (range: \[0 - 21\]). Higher scores indicate worse sleep quality.

Nutritional score (natural number, range \[0 - 100\]) calculated using the in-house Food Frequency Questionnaire. A score of \> 70 indicates healthy dietary behaviour.

Food intake in kcal per day calculated using the in-house Food Frequency Questionnaire.

Calculated from multiple frequency bio-impedance measurements (in %, range \[0 - 100\]).

Waist circumference (cm) divided by hip circumference (cm)

In kilograms (kg), measured by handheld dynamometer.

KU Leuven

Universitaire Ziekenhuizen KU Leuven

Inflammation

Channel Blockers

Analgesics

Anticonvulsants

Psychotropic Drugs

Anti-Inflammatory Agents

Antirheumatic Agents

Bone Density Conservation Agents

Pregabalin

Ketorolac

Ketorolac Tromethamine

Calcium

Calcium Channel Blockers

Calcium, Dietary

Hormones

Anti-Anxiety Agents

Anti-Inflammatory Agents, Non-Steroidal

Analgesics, Non-Narcotic

Cyclooxygenase Inhibitors

Enzyme Inhibitors

Control group: Standard of care

Number of subjects: 28 (14 lean patients, defined as Body mass index \<25 kg/m², and 14 overweight/obese patients, defined as BMI ≥25 kg/m² )

Investigational Medicinal Product (IMP): Ketorolac

Number of subjects: 28 (14 lean patients, defined as Body mass index \<25 kg/m², and 14 overweight/obese patients, defined as BMI ≥25 kg/m² )

Investigational Medicinal Product (IMP): Pregabalin

Number of subjects: 28 (14 lean patients, defined as Body mass index \<25 kg/m², and 14 overweight/obese patients, defined as BMI ≥25 kg/m² )

Investigational Medicinal Products (IMPs): Ketorolac and pregabalin

Number of subjects: 28 (14 lean patients, defined as Body mass index \<25 kg/m², and 14 overweight/obese patients, defined as BMI ≥25 kg/m² )

Core-needle biopsy of the breast (pre-treatment), surgical sample collection (post-treatment), extra collection of blood samples (pre- and post-treatment), measurements of adiposity

Patients will receive 10 mg film-coated tablets of ketorolac tromethamine three times a day, for five days before the surgery

Ketorolac 10 Mg Oral Tablet

Patients will receive 75 mg of pregabalin hard capsule twice a day, for seven days before the surgery

Pregabalin 75mg

Imane Bachir, MD

Maher Khalife, MD

Laurence Buisseret, MD, Phd

Isabelle Veys, MD

Elia Biganzoli, PhD

Juan A Rodriguez Arango, MD

Denis Larsimont, MD, PhD

Out of all proportion to its short duration, the perioperative period is critical in determining the long-term outcome of cancer.

To contribute to a better understanding of the neural and inflammatory mechanisms underlying this issue, we aim to implement a novel intervention based on the preoperative use of non-steroidal anti-inflammatory drugs (NSAIDs) with or without an anti-epileptic drug.

Our goal is to understand and transform the perioperative window from being a facilitator of metastatic progression to arresting and/or eliminating residual disease using repurposing drugs

The perioperative period presents a unique window of therapeutic opportunities to counteract minimal residual growth and dormancy escape of cancer cells. The main physiological disturbances induced by the surgery, that enhance the tumoral growth in the perioperative period, are due to the neuronal and inflammatory signaling.

We propose a therapeutic modelling of the inflammatory and neurological pathways in a phase II trial using ketorolac and pregabalin, alone or in combination. Ketorolac, a non-selective NSAIDs will target cyclooxygenase (COX)-enzymes, while pregabalin, an anti-epileptic drug will regulates the release of neurotransmitters. Moreover, both drugs have an effect on the postoperative pain and pregabalin has anxiolytic property. Thanks to this study, and through specific blockade, we want to understand how nervous and inflammatory systems remodel the tumour and systemic characteristics. To ensure an integrative analysis of those factors, patient's adiposity as well as other confounding variable will be taken into account.

Ketorolac and Pregabalin Effects on breaSt Cancer (KePreSt)

Unravelling the Local and Systemic Effects of Primary Surgery and Perioperative Use of Ketorolac and Pregabalin in Primary Breast Cancer Patients According to Adiposity

Calculated from multiple frequency bio-impedance measurements (in %, range \[0 - 100\])

Plasma multiplex technology using cytometric bead arrays

Liquid Chromatography coupled to tandem Mass Spectrometry (LC-MS/MS)

Transcriptome profile and bioinformatic analysis

Characterization of Tumour-infiltrating leukocyte subpopulations using RNA sequencing analysis from fresh frozen tissue sections

Level of neurogenesis markers using RNA sequencing analysis from fresh frozen tissue section

Using RNA sequencing analysis from fresh frozen tissue sections

Fluorescence activated cell sorting (FACS) analysis

Generalized Anxiety Disorder - 7 (GAD - 7) Anxiety score (natural number, range\[0 - 21\]. A score comprised between 0 - 4 indicates a minimal anxiety, 5-9 a mild anxiety, 10-14 a moderate anxiety and a 15-21 in a severe anxiety.

Consumption of morphine delivered by a programmable patient-controlled analgesia (PCA) infusion pump (number of requested and effectively delivered bolus/ 24h)

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
The Healthy Diet and Lifestyle Study	NCT03639350	Visceral Fat	IER+MED group DASH group	35 Years - 55 Years	University of Hawaii
Nutrition Childhood Cancer Survivors	NCT05481229	Childhood Cance... Nutrition Disor...	nutritional int...	18 Years - 64 Years	Masaryk University
Neuroendocrine Mechanisms in Adiposity: An Integrated Approach to the Characterization of Potential Pharmacological Novel Targets Based on Experimental and Clinical Models	NCT06326853	Endocrine Disor... Adiposity Pituitary Adeno... Cushing Syndrom... Acromegaly Hypopituitarism		18 Years -	IRCCS San Raffaele
Alberta Physical Activity and Breast Cancer Prevention (ALPHA) Trial	NCT00522262	Breast Neoplasm...	Aerobic exercis...	50 Years - 74 Years	AHS Cancer Control Alberta
FATLAS: Comprehensive Multi-level Characterization of Systemic and Mammary Adiposity in Breast Cancer Patients.	NCT04200768	Breast Neoplasm...	Prospective dat...	18 Years - 75 Years	Universitaire Ziekenhuizen KU Leuven
Nutrition Childhood Cancer Survivors	NCT05481229	Childhood Cance... Nutrition Disor...	nutritional int...	18 Years - 64 Years	Masaryk University
Ketorolac and Pregabalin Effects on breaSt Cancer (KePreSt)	NCT06150898	Early-stage Bre... Estrogen-recept...	Prospective dat... Ketorolac 10 Mg... Pregabalin 75mg	18 Years - 70 Years	Jules Bordet Institute
FATLAS: Comprehensive Multi-level Characterization of Systemic and Mammary Adiposity in Breast Cancer Patients.	NCT04200768	Breast Neoplasm...	Prospective dat...	18 Years - 75 Years	Universitaire Ziekenhuizen KU Leuven
Nutrition Childhood Cancer Survivors	NCT05481229	Childhood Cance... Nutrition Disor...	nutritional int...	18 Years - 64 Years	Masaryk University
FATLAS: Comprehensive Multi-level Characterization of Systemic and Mammary Adiposity in Breast Cancer Patients.	NCT04200768	Breast Neoplasm...	Prospective dat...	18 Years - 75 Years	Universitaire Ziekenhuizen KU Leuven
The Healthy Diet and Lifestyle Study	NCT03639350	Visceral Fat	IER+MED group DASH group	35 Years - 55 Years	University of Hawaii
Ketorolac and Pregabalin Effects on breaSt Cancer (KePreSt)	NCT06150898	Early-stage Bre... Estrogen-recept...	Prospective dat... Ketorolac 10 Mg... Pregabalin 75mg	18 Years - 70 Years	Jules Bordet Institute

Spots Global Cancer Trial Database for adiposity

Every month we try and update this database with for adiposity cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for adiposity

Every month we try and update this database with for adiposity cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for adiposity cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.